JP2005521393A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005521393A5 JP2005521393A5 JP2003577602A JP2003577602A JP2005521393A5 JP 2005521393 A5 JP2005521393 A5 JP 2005521393A5 JP 2003577602 A JP2003577602 A JP 2003577602A JP 2003577602 A JP2003577602 A JP 2003577602A JP 2005521393 A5 JP2005521393 A5 JP 2005521393A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- sirna
- transcript
- infectious agent
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 89
- 108020004459 Small interfering RNA Proteins 0.000 claims 53
- 210000004027 cell Anatomy 0.000 claims 48
- 239000012678 infectious agent Substances 0.000 claims 38
- 208000015181 infectious disease Diseases 0.000 claims 27
- 241000700605 Viruses Species 0.000 claims 21
- 239000013598 vector Substances 0.000 claims 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 230000010076 replication Effects 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 6
- 230000001105 regulatory effect Effects 0.000 claims 5
- 230000015556 catabolic process Effects 0.000 claims 4
- 238000006731 degradation reaction Methods 0.000 claims 4
- 230000001934 delay Effects 0.000 claims 4
- 230000004048 modification Effects 0.000 claims 4
- 238000012986 modification Methods 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 230000002458 infectious effect Effects 0.000 claims 3
- 230000010468 interferon response Effects 0.000 claims 3
- 230000009467 reduction Effects 0.000 claims 3
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 241000713666 Lentivirus Species 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- 241001430294 unidentified retrovirus Species 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- AWGBKZRMLNVLAF-UHFFFAOYSA-N 3,5-dibromo-n,2-dihydroxybenzamide Chemical compound ONC(=O)C1=CC(Br)=CC(Br)=C1O AWGBKZRMLNVLAF-UHFFFAOYSA-N 0.000 claims 1
- 108020004394 Complementary RNA Proteins 0.000 claims 1
- 102000014450 RNA Polymerase III Human genes 0.000 claims 1
- 108010078067 RNA Polymerase III Proteins 0.000 claims 1
- 108091028664 Ribonucleotide Proteins 0.000 claims 1
- 108010067390 Viral Proteins Proteins 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 239000005547 deoxyribonucleotide Substances 0.000 claims 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 230000008569 process Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 239000002336 ribonucleotide Substances 0.000 claims 1
- 125000002652 ribonucleotide group Chemical group 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
- 230000014616 translation Effects 0.000 claims 1
- 230000029812 viral genome replication Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36592502P | 2002-03-20 | 2002-03-20 | |
| US39604102P | 2002-07-15 | 2002-07-15 | |
| PCT/US2003/008653 WO2003079757A2 (en) | 2002-03-20 | 2003-03-20 | Hiv therapeutic |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005521393A JP2005521393A (ja) | 2005-07-21 |
| JP2005521393A5 true JP2005521393A5 (enExample) | 2006-05-11 |
Family
ID=28457122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003577602A Pending JP2005521393A (ja) | 2002-03-20 | 2003-03-20 | Ｈｉｖ治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20040248296A1 (enExample) |
| EP (1) | EP1495141A4 (enExample) |
| JP (1) | JP2005521393A (enExample) |
| AU (1) | AU2003224725A1 (enExample) |
| CA (1) | CA2479530A1 (enExample) |
| WO (1) | WO2003079757A2 (enExample) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| KR20080023768A (ko) | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체 |
| CN100523215C (zh) | 2000-12-01 | 2009-08-05 | 马普科技促进协会 | 介导rna干涉的小rna分子 |
| AU2003261449A1 (en) | 2002-08-07 | 2004-02-25 | Compositions for rna interference and methods of use thereof | |
| EP2000160A3 (en) * | 2002-10-30 | 2009-03-11 | Gambro Lundia AB | Method and apparatuses for determining the efficiency of dialysis |
| US8198427B1 (en) | 2002-11-14 | 2012-06-12 | Dharmacon, Inc. | SiRNA targeting catenin, beta-1 (CTNNB1) |
| US9719094B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting SEC61G |
| US7977471B2 (en) * | 2002-11-14 | 2011-07-12 | Dharmacon, Inc. | siRNA targeting TNFα |
| US9228186B2 (en) | 2002-11-14 | 2016-01-05 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US7635770B2 (en) * | 2002-11-14 | 2009-12-22 | Dharmacon, Inc. | siRNA targeting protein kinase N-3 (PKN-3) |
| US7951935B2 (en) | 2002-11-14 | 2011-05-31 | Dharmacon, Inc. | siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC) |
| US9839649B2 (en) | 2002-11-14 | 2017-12-12 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US7781575B2 (en) | 2002-11-14 | 2010-08-24 | Dharmacon, Inc. | siRNA targeting tumor protein 53 (p53) |
| US7592442B2 (en) * | 2002-11-14 | 2009-09-22 | Dharmacon, Inc. | siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2) |
| US20100113307A1 (en) * | 2002-11-14 | 2010-05-06 | Dharmacon, Inc. | siRNA targeting vascular endothelial growth factor (VEGF) |
| EP2305813A3 (en) * | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| US20080268457A1 (en) * | 2002-11-14 | 2008-10-30 | Dharmacon, Inc. | siRNA targeting forkhead box P3 (FOXP3) |
| US7619081B2 (en) * | 2002-11-14 | 2009-11-17 | Dharmacon, Inc. | siRNA targeting coatomer protein complex, subunit beta 2 (COPB2) |
| US20090227780A1 (en) * | 2002-11-14 | 2009-09-10 | Dharmacon, Inc. | siRNA targeting connexin 43 |
| US9719092B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting CNTD2 |
| US7612196B2 (en) * | 2002-11-14 | 2009-11-03 | Dharmacon, Inc. | siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B) |
| US9879266B2 (en) | 2002-11-14 | 2018-01-30 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| US9771586B2 (en) | 2002-11-14 | 2017-09-26 | Thermo Fisher Scientific Inc. | RNAi targeting ZNF205 |
| US7691998B2 (en) * | 2002-11-14 | 2010-04-06 | Dharmacon, Inc. | siRNA targeting nucleoporin 62kDa (Nup62) |
| US10011836B2 (en) | 2002-11-14 | 2018-07-03 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| WO2004047764A2 (en) * | 2002-11-22 | 2004-06-10 | University Of Massachusetts | Modulation of hiv replication by rna interference |
| CA2513679A1 (en) | 2003-01-17 | 2004-08-05 | University Of Florida | Small interference rna gene therapy |
| US20050059044A1 (en) * | 2003-06-03 | 2005-03-17 | Graham Michael Wayne | Double-stranded nucleic acid |
| WO2005012483A2 (en) * | 2003-08-01 | 2005-02-10 | International Therapeutics, Inc. | Vpr selective rnai agents and methods for using the same |
| EP1663315B1 (en) * | 2003-09-17 | 2011-01-05 | Rodos BioTarget GmbH | Targeted lipid-drug formulations for delivery of drugs to myeloid and lymphoid immune cells |
| EP1678312A1 (en) * | 2003-10-22 | 2006-07-12 | Aventis Pharmaceuticals, Inc. | Retroviral vectors for delivery of interfering rna |
| ATE508190T1 (de) * | 2004-03-05 | 2011-05-15 | Benitec Inc | Mehrfachpromotor-expressionskassetten zurgleichzeitigen zuführung von rnai-agentien |
| CA2559955C (en) | 2004-03-15 | 2016-02-16 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded rna |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| US7605250B2 (en) * | 2004-05-12 | 2009-10-20 | Dharmacon, Inc. | siRNA targeting cAMP-specific phosphodiesterase 4D |
| EP1627563A1 (en) | 2004-08-10 | 2006-02-22 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Means and methods for producing a stabilized cell of interest |
| WO2006023491A2 (en) | 2004-08-16 | 2006-03-02 | The Cbr Institute For Biomedical Research, Inc. | Method of delivering rna interference and uses thereof |
| EP1796732B1 (en) * | 2004-10-01 | 2013-10-30 | Novartis Vaccines and Diagnostics, Inc. | Modified small interfering rna molecules and methods of use |
| US8765704B1 (en) | 2008-02-28 | 2014-07-01 | Novartis Ag | Modified small interfering RNA molecules and methods of use |
| JP4131271B2 (ja) * | 2005-03-30 | 2008-08-13 | ソニー株式会社 | 情報処理装置および方法、並びにプログラム |
| CA2630348C (en) | 2005-11-17 | 2016-01-12 | Stichting Voor De Technische Wetenschappen | Inducible expression systems |
| USRE49583E1 (en) | 2005-11-17 | 2023-07-18 | Tet Systems Gmbh & Co. Kg | Inducible expression systems |
| NZ600075A (en) | 2005-12-09 | 2013-12-20 | Amc Amsterdam | Means and methods for influencing the stability of antibody producing cells |
| US9005974B2 (en) | 2005-12-09 | 2015-04-14 | Academish Medisch Centrum Bij De Universiteit Van Amsterdam | Means and methods for influencing the stability of cells |
| WO2008118013A2 (en) | 2007-03-23 | 2008-10-02 | To-Bbb Holding B.V. | Targeted intracellular delivery of antiviral agents |
| AU2008338526A1 (en) * | 2007-12-14 | 2009-06-25 | Immune Disease Institute, Inc. | Treatment and prevention of HIV infection |
| WO2010045659A1 (en) | 2008-10-17 | 2010-04-22 | American Gene Technologies International Inc. | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
| EP2425001A4 (en) | 2009-04-30 | 2012-11-14 | Univ California | ANTI-HIV COMBINATION VECTORS, TARGETING VECTORS AND METHOD OF USE |
| WO2011008093A1 (en) | 2009-07-15 | 2011-01-20 | Aimm Therapeutics B.V. | Means and methods for producing high affinity antibodies |
| US9799416B2 (en) * | 2009-11-06 | 2017-10-24 | Terrapower, Llc | Methods and systems for migrating fuel assemblies in a nuclear fission reactor |
| CU23896B1 (es) * | 2010-04-01 | 2013-05-31 | Ct De Ingeniería Genética Y Biotecnología | Método para inhibir la replicación del vih en células de mamíferos |
| SG186899A1 (en) | 2010-07-08 | 2013-02-28 | Bonac Corp | Single-strand nucleic acid molecule for controlling gene expression |
| ES2533129T3 (es) | 2010-08-03 | 2015-04-07 | Bonac Corporation | Molécula de ARN monocatenario que tiene esqueleto alicíclico que contiene nitrógeno |
| US20120310140A1 (en) | 2010-12-01 | 2012-12-06 | Spinal Modulation, Inc. | Directed delivery of agents to neural anatomy |
| WO2012072814A1 (en) | 2010-12-02 | 2012-06-07 | Aimm Therapeutics B.V. | Means and methods for producing high affinity antibodies |
| WO2013077446A1 (ja) * | 2011-11-26 | 2013-05-30 | 株式会社ボナック | 遺伝子発現制御のための一本鎖核酸分子 |
| US9663784B2 (en) | 2012-05-26 | 2017-05-30 | Bonac Corporation | Single-stranded nucleic acid molecule for regulating expression of gene having delivering function |
| WO2015099122A1 (ja) | 2013-12-26 | 2015-07-02 | 学校法人東京医科大学 | 遺伝子発現制御のための人工ミミックｍｉＲＮＡおよびその用途 |
| SG10201805087VA (en) | 2013-12-27 | 2018-07-30 | Bonac Corp | Artificial match-type mirna for controlling gene expression and use therefor |
| DK3099709T3 (da) | 2014-01-31 | 2020-02-03 | Aimm Therapeutics Bv | Midler og fremgangsmåder til fremstilling af stabile antistoffer |
| WO2016104775A1 (ja) | 2014-12-27 | 2016-06-30 | 株式会社ボナック | 遺伝子発現制御のための天然型ｍｉＲＮＡおよびその用途 |
| JP6602847B2 (ja) | 2015-03-27 | 2019-11-06 | 株式会社ボナック | デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子 |
| US11980663B2 (en) | 2015-07-08 | 2024-05-14 | American Gene Technologies International Inc. | HIV pre-immunization and immunotherapy |
| IL297238B2 (en) | 2016-01-15 | 2024-08-01 | American Gene Tech Int Inc | Methods and preparations for gamma-delta T-cell activation |
| US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
| JP7153332B2 (ja) | 2016-02-08 | 2022-10-14 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | Ｈｉｖワクチン接種および免疫療法 |
| ES2911448T3 (es) | 2016-03-09 | 2022-05-19 | American Gene Tech Int Inc | Vectores combinados y métodos para el tratamiento del cáncer |
| WO2017213697A1 (en) | 2016-06-08 | 2017-12-14 | American Gene Technologies International Inc. | Non-integrating viral delivery system and methods related thereto |
| CA3028982A1 (en) | 2016-07-08 | 2018-01-11 | American Gene Technologies International Inc. | Hiv pre-immunization and immunotherapy |
| WO2018017882A1 (en) | 2016-07-21 | 2018-01-25 | American Gene Technologies International Inc. | Viral vectors for treating parkinson's disease |
| US11820999B2 (en) | 2017-04-03 | 2023-11-21 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
| US12559769B2 (en) | 2017-06-16 | 2026-02-24 | American Gene Technologies International Inc. | Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells |
| EP3876952A4 (en) | 2018-11-05 | 2022-08-24 | American Gene Technologies International Inc. | VECTOR SYSTEM FOR EXPRESSING REGULATORY RNA |
| JP2023524679A (ja) | 2020-04-30 | 2023-06-13 | フィジーン、エルエルシー | 癌線維芽細胞を標的化するための免疫療法の方法および組成物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5866701A (en) * | 1988-09-20 | 1999-02-02 | The Board Of Regents For Northern Illinois University Of Dekalb | HIV targeted hairpin ribozymes |
| US5693535A (en) * | 1992-05-14 | 1997-12-02 | Ribozyme Pharmaceuticals, Inc. | HIV targeted ribozymes |
| US5714320A (en) * | 1993-04-15 | 1998-02-03 | University Of Rochester | Rolling circle synthesis of oligonucleotides and amplification of select randomized circular oligonucleotides |
| KR960702518A (ko) * | 1993-05-17 | 1996-04-27 | 린다 에스, 스티븐슨 | Hiv 감염 및 aids에 대한 리보자임 유전자 치료(ribozyme gene therapy for hiv infection and aids) |
| US5712384A (en) * | 1994-01-05 | 1998-01-27 | Gene Shears Pty Ltd. | Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs |
| US5922695A (en) * | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| AU776150B2 (en) * | 1999-01-28 | 2004-08-26 | Medical College Of Georgia Research Institute, Inc. | Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA |
| KR20080023768A (ko) * | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체 |
| CN100523215C (zh) * | 2000-12-01 | 2009-08-05 | 马普科技促进协会 | 介导rna干涉的小rna分子 |
| US20030175950A1 (en) * | 2001-05-29 | 2003-09-18 | Mcswiggen James A. | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
| CA2457282C (en) * | 2001-09-13 | 2015-01-13 | California Institute Of Technology | Method for expression of small antiviral rna molecules within a cell |
| US20030203868A1 (en) * | 2002-02-06 | 2003-10-30 | Bushman Frederic D. | Inhibition of pathogen replication by RNA interference |
-
2003
- 2003-03-20 WO PCT/US2003/008653 patent/WO2003079757A2/en not_active Ceased
- 2003-03-20 JP JP2003577602A patent/JP2005521393A/ja active Pending
- 2003-03-20 AU AU2003224725A patent/AU2003224725A1/en not_active Abandoned
- 2003-03-20 EP EP03721410A patent/EP1495141A4/en not_active Withdrawn
- 2003-03-20 CA CA002479530A patent/CA2479530A1/en not_active Abandoned
- 2003-03-20 US US10/393,411 patent/US20040248296A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8846632B2 (en) | Nucleic acids for targeting multiple regions of the HCV genome | |
| JP4718379B2 (ja) | 修飾された低分子干渉ｒｎａ分子および使用方法 | |
| CA2853613C (en) | Hbv treatment | |
| US20110117608A1 (en) | Double-stranded nucleic acid | |
| KR20120008094A (ko) | ＲＮＡｉ 제제의 동시 전달을 위한 다중 프로모터 발현 카세트 | |
| US8871919B2 (en) | RNAi therapeutic for treatment of Hepatitis C infection | |
| Kim et al. | Multiple shRNAs driven by U6 and CMV promoter enhances efficiency of antiviral effects against foot-and-mouth disease virus | |
| JP4545091B2 (ja) | Ｃ型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸 | |
| Hong et al. | RNA interference targeting WSSV ribonucleotide reductase 2 provides long-term protection against infection in Litopenaeus vannamei | |
| WO2009002918A2 (en) | Hepatitis c dsrna effector molecules, expression constructs, compositions, and methods of use | |
| US9574195B2 (en) | RNAi agent for inhibition of Chikungunya virus | |
| KR101077188B1 (ko) | 구제역 바이러스 억제를 위한 ｓｉＲＮＡ를 발현하는 재조합 아데노바이러스 | |
| AU2004243347B2 (en) | Double-stranded nucleic acid | |
| US20100286238A1 (en) | Suppression of viruses involved in respiratory infection or disease | |
| Ely et al. | 799. Expressed Long Hairpin RNA Sequences Inhibit HBV Replication In Vivo without Inducing an Interferon Response | |
| WO2012109798A1 (en) | Hbv treatment | |
| JPWO2021020412A5 (enExample) | ||
| JP2013223426A (ja) | Ｒｒｍ２のアンタゴニストを有効成分として含有するｃ型肝炎治療剤 |